Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H1 2018

  • ID: 4482740
  • Drug Pipelines
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnGes Inc
  • F-star Biotechnology Ltd
  • Kringle Pharma Inc
  • M3 Biotechnology Inc
  • Molecular Partners AG
  • ViroMed Co Ltd
  • MORE
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H1 2018

Summary:

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 4 and 2 respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Metabolic Disorders which include indications Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Gastric Cancer, Melanoma, Myocardial Infarction, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Advanced Malignancy, Angina (Angina Pectoris), Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Nasopharyngeal Cancer, Parkinson's Disease, Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Thromboangiitis obliterans (Buerger disease).

The latest report Hepatocyte Growth Factor - Pipeline Review, H1 2018, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnGes Inc
  • F-star Biotechnology Ltd
  • Kringle Pharma Inc
  • M3 Biotechnology Inc
  • Molecular Partners AG
  • ViroMed Co Ltd
  • MORE
Introduction

Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development

AnGes Inc

F-star Biotechnology Ltd

Kringle Pharma Inc

M3 Biotechnology Inc

Minerva Biotechnologies Corp

Molecular Partners AG

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles

beperminogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy 1 to Activate HGF for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDX-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones

Featured News & Press Releases

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Jan 08, 2018: Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma

Nov 09, 2017: ViroMed Builds Team of Experts to Complete New Global Drug Development

Oct 30, 2017: VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM

Oct 17, 2017: M3 Biotechnology Launches Clinical Trials for Alzheimer’s Disease Drug Focused on Restoring Lost Connections in the Brain

Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage

Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers

Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials

Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials

Feb 09, 2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)

Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AnGes Inc, H1 2018

Pipeline by F-star Biotechnology Ltd, H1 2018

Pipeline by Kringle Pharma Inc, H1 2018

Pipeline by M3 Biotechnology Inc, H1 2018

Pipeline by Minerva Biotechnologies Corp, H1 2018

Pipeline by Molecular Partners AG, H1 2018

Pipeline by ViroMed Co Ltd, H1 2018

Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2018

Pipeline by Yooyoung Pharm Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AnGes Inc
  • F-star Biotechnology Ltd
  • Kringle Pharma Inc
  • M3 Biotechnology Inc
  • Minerva Biotechnologies Corp
  • Molecular Partners AG
  • ViroMed Co Ltd
  • YiChang Humanwell Pharmaceutical Co Ltd
  • Yooyoung Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll